Breaking News, Collaborations & Alliances

RedHill Licenses RHB-102 to Hyloris

If approved, RHB-102 will provide the opportunity to deliver 24-hour relief from nausea and vomiting in a single pill.

Author Image

By: Charlie Sternberg

Associate Editor

RedHill Biopharma Ltd., a specialty biopharmaceutical company, has entered into an exclusive worldwide development and commercialization licensing agreement, excluding North America, with Hyloris Pharmaceuticals SA for RedHill’s RHB-102 (Bekinda). Under the terms of the Agreement, Hyloris will pay RedHill an upfront payment, in addition to up to $60 million in potential milestone payments, contingent upon achieving specified commercial targets, plus up to mid-20s percent royalties on re...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters